The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Antibody and Recombinant Protein CDMO Market Research Report 2025
Synopsis
The global Antibody and Recombinant Protein CDMO market was valued at US$ 51310 million in 2023 and is anticipated to reach US$ 83480 million by 2030, witnessing a CAGR of 7.0% during the forecast period 2024-2030.
North American market for Antibody and Recombinant Protein CDMO is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Antibody and Recombinant Protein CDMO is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Antibody and Recombinant Protein CDMO in Pharmaceutical Company is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Antibody and Recombinant Protein CDMO include Batavia Biosciences, Grifols, Cerbios-Pharma SA, HALIX, Biovian Oy, Catalent, Goodwin Biotechnology, Merck and Hangzhou Hs-biopharm, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Antibody and Recombinant Protein CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibody and Recombinant Protein CDMO.
Report Scope
The Antibody and Recombinant Protein CDMO market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Antibody and Recombinant Protein CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antibody and Recombinant Protein CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Batavia Biosciences
Grifols
Cerbios-Pharma SA
HALIX
Biovian Oy
Catalent
Goodwin Biotechnology
Merck
Hangzhou Hs-biopharm
Wuxibiologics
Bioinnobio
Thousand Oaks Biopharmaceuticals
Eurogentec
HJB
Bibo Pharma
MabPlex International
Genscriptprobio
Vetter
Etinpro (Beijing) Co
Boehringer Ingelheim BioXcellence
Lonza
3SBio Inc
Porton
Segment by Type
Antibody CDMO
Recombinant Protein CDMO
Segment by Application
Pharmaceutical Company
Biotechnology Company
Generic Company
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antibody and Recombinant Protein CDMO companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Antibody and Recombinant Protein CDMO market was valued at US$ 51310 million in 2023 and is anticipated to reach US$ 83480 million by 2030, witnessing a CAGR of 7.0% during the forecast period 2024-2030.
North American market for Antibody and Recombinant Protein CDMO is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Antibody and Recombinant Protein CDMO is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Antibody and Recombinant Protein CDMO in Pharmaceutical Company is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Antibody and Recombinant Protein CDMO include Batavia Biosciences, Grifols, Cerbios-Pharma SA, HALIX, Biovian Oy, Catalent, Goodwin Biotechnology, Merck and Hangzhou Hs-biopharm, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Antibody and Recombinant Protein CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibody and Recombinant Protein CDMO.
Report Scope
The Antibody and Recombinant Protein CDMO market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Antibody and Recombinant Protein CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antibody and Recombinant Protein CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Batavia Biosciences
Grifols
Cerbios-Pharma SA
HALIX
Biovian Oy
Catalent
Goodwin Biotechnology
Merck
Hangzhou Hs-biopharm
Wuxibiologics
Bioinnobio
Thousand Oaks Biopharmaceuticals
Eurogentec
HJB
Bibo Pharma
MabPlex International
Genscriptprobio
Vetter
Etinpro (Beijing) Co
Boehringer Ingelheim BioXcellence
Lonza
3SBio Inc
Porton
Segment by Type
Antibody CDMO
Recombinant Protein CDMO
Segment by Application
Pharmaceutical Company
Biotechnology Company
Generic Company
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antibody and Recombinant Protein CDMO companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antibody and Recombinant Protein CDMO Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Antibody CDMO
1.2.3 Recombinant Protein CDMO
1.3 Market by Application
1.3.1 Global Antibody and Recombinant Protein CDMO Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Pharmaceutical Company
1.3.3 Biotechnology Company
1.3.4 Generic Company
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Antibody and Recombinant Protein CDMO Market Perspective (2019-2030)
2.2 Antibody and Recombinant Protein CDMO Growth Trends by Region
2.2.1 Global Antibody and Recombinant Protein CDMO Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Antibody and Recombinant Protein CDMO Historic Market Size by Region (2019-2024)
2.2.3 Antibody and Recombinant Protein CDMO Forecasted Market Size by Region (2025-2030)
2.3 Antibody and Recombinant Protein CDMO Market Dynamics
2.3.1 Antibody and Recombinant Protein CDMO Industry Trends
2.3.2 Antibody and Recombinant Protein CDMO Market Drivers
2.3.3 Antibody and Recombinant Protein CDMO Market Challenges
2.3.4 Antibody and Recombinant Protein CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Antibody and Recombinant Protein CDMO Players by Revenue
3.1.1 Global Top Antibody and Recombinant Protein CDMO Players by Revenue (2019-2024)
3.1.2 Global Antibody and Recombinant Protein CDMO Revenue Market Share by Players (2019-2024)
3.2 Global Antibody and Recombinant Protein CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Antibody and Recombinant Protein CDMO Revenue
3.4 Global Antibody and Recombinant Protein CDMO Market Concentration Ratio
3.4.1 Global Antibody and Recombinant Protein CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antibody and Recombinant Protein CDMO Revenue in 2023
3.5 Antibody and Recombinant Protein CDMO Key Players Head office and Area Served
3.6 Key Players Antibody and Recombinant Protein CDMO Product Solution and Service
3.7 Date of Enter into Antibody and Recombinant Protein CDMO Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Antibody and Recombinant Protein CDMO Breakdown Data by Type
4.1 Global Antibody and Recombinant Protein CDMO Historic Market Size by Type (2019-2024)
4.2 Global Antibody and Recombinant Protein CDMO Forecasted Market Size by Type (2025-2030)
5 Antibody and Recombinant Protein CDMO Breakdown Data by Application
5.1 Global Antibody and Recombinant Protein CDMO Historic Market Size by Application (2019-2024)
5.2 Global Antibody and Recombinant Protein CDMO Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Antibody and Recombinant Protein CDMO Market Size (2019-2030)
6.2 North America Antibody and Recombinant Protein CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Antibody and Recombinant Protein CDMO Market Size by Country (2019-2024)
6.4 North America Antibody and Recombinant Protein CDMO Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Antibody and Recombinant Protein CDMO Market Size (2019-2030)
7.2 Europe Antibody and Recombinant Protein CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Antibody and Recombinant Protein CDMO Market Size by Country (2019-2024)
7.4 Europe Antibody and Recombinant Protein CDMO Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Antibody and Recombinant Protein CDMO Market Size (2019-2030)
8.2 Asia-Pacific Antibody and Recombinant Protein CDMO Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Antibody and Recombinant Protein CDMO Market Size by Region (2019-2024)
8.4 Asia-Pacific Antibody and Recombinant Protein CDMO Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Antibody and Recombinant Protein CDMO Market Size (2019-2030)
9.2 Latin America Antibody and Recombinant Protein CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Antibody and Recombinant Protein CDMO Market Size by Country (2019-2024)
9.4 Latin America Antibody and Recombinant Protein CDMO Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Antibody and Recombinant Protein CDMO Market Size (2019-2030)
10.2 Middle East & Africa Antibody and Recombinant Protein CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Antibody and Recombinant Protein CDMO Market Size by Country (2019-2024)
10.4 Middle East & Africa Antibody and Recombinant Protein CDMO Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Batavia Biosciences
11.1.1 Batavia Biosciences Company Detail
11.1.2 Batavia Biosciences Business Overview
11.1.3 Batavia Biosciences Antibody and Recombinant Protein CDMO Introduction
11.1.4 Batavia Biosciences Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024)
11.1.5 Batavia Biosciences Recent Development
11.2 Grifols
11.2.1 Grifols Company Detail
11.2.2 Grifols Business Overview
11.2.3 Grifols Antibody and Recombinant Protein CDMO Introduction
11.2.4 Grifols Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024)
11.2.5 Grifols Recent Development
11.3 Cerbios-Pharma SA
11.3.1 Cerbios-Pharma SA Company Detail
11.3.2 Cerbios-Pharma SA Business Overview
11.3.3 Cerbios-Pharma SA Antibody and Recombinant Protein CDMO Introduction
11.3.4 Cerbios-Pharma SA Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024)
11.3.5 Cerbios-Pharma SA Recent Development
11.4 HALIX
11.4.1 HALIX Company Detail
11.4.2 HALIX Business Overview
11.4.3 HALIX Antibody and Recombinant Protein CDMO Introduction
11.4.4 HALIX Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024)
11.4.5 HALIX Recent Development
11.5 Biovian Oy
11.5.1 Biovian Oy Company Detail
11.5.2 Biovian Oy Business Overview
11.5.3 Biovian Oy Antibody and Recombinant Protein CDMO Introduction
11.5.4 Biovian Oy Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024)
11.5.5 Biovian Oy Recent Development
11.6 Catalent
11.6.1 Catalent Company Detail
11.6.2 Catalent Business Overview
11.6.3 Catalent Antibody and Recombinant Protein CDMO Introduction
11.6.4 Catalent Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024)
11.6.5 Catalent Recent Development
11.7 Goodwin Biotechnology
11.7.1 Goodwin Biotechnology Company Detail
11.7.2 Goodwin Biotechnology Business Overview
11.7.3 Goodwin Biotechnology Antibody and Recombinant Protein CDMO Introduction
11.7.4 Goodwin Biotechnology Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024)
11.7.5 Goodwin Biotechnology Recent Development
11.8 Merck
11.8.1 Merck Company Detail
11.8.2 Merck Business Overview
11.8.3 Merck Antibody and Recombinant Protein CDMO Introduction
11.8.4 Merck Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024)
11.8.5 Merck Recent Development
11.9 Hangzhou Hs-biopharm
11.9.1 Hangzhou Hs-biopharm Company Detail
11.9.2 Hangzhou Hs-biopharm Business Overview
11.9.3 Hangzhou Hs-biopharm Antibody and Recombinant Protein CDMO Introduction
11.9.4 Hangzhou Hs-biopharm Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024)
11.9.5 Hangzhou Hs-biopharm Recent Development
11.10 Wuxibiologics
11.10.1 Wuxibiologics Company Detail
11.10.2 Wuxibiologics Business Overview
11.10.3 Wuxibiologics Antibody and Recombinant Protein CDMO Introduction
11.10.4 Wuxibiologics Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024)
11.10.5 Wuxibiologics Recent Development
11.11 Bioinnobio
11.11.1 Bioinnobio Company Detail
11.11.2 Bioinnobio Business Overview
11.11.3 Bioinnobio Antibody and Recombinant Protein CDMO Introduction
11.11.4 Bioinnobio Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024)
11.11.5 Bioinnobio Recent Development
11.12 Thousand Oaks Biopharmaceuticals
11.12.1 Thousand Oaks Biopharmaceuticals Company Detail
11.12.2 Thousand Oaks Biopharmaceuticals Business Overview
11.12.3 Thousand Oaks Biopharmaceuticals Antibody and Recombinant Protein CDMO Introduction
11.12.4 Thousand Oaks Biopharmaceuticals Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024)
11.12.5 Thousand Oaks Biopharmaceuticals Recent Development
11.13 Eurogentec
11.13.1 Eurogentec Company Detail
11.13.2 Eurogentec Business Overview
11.13.3 Eurogentec Antibody and Recombinant Protein CDMO Introduction
11.13.4 Eurogentec Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024)
11.13.5 Eurogentec Recent Development
11.14 HJB
11.14.1 HJB Company Detail
11.14.2 HJB Business Overview
11.14.3 HJB Antibody and Recombinant Protein CDMO Introduction
11.14.4 HJB Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024)
11.14.5 HJB Recent Development
11.15 Bibo Pharma
11.15.1 Bibo Pharma Company Detail
11.15.2 Bibo Pharma Business Overview
11.15.3 Bibo Pharma Antibody and Recombinant Protein CDMO Introduction
11.15.4 Bibo Pharma Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024)
11.15.5 Bibo Pharma Recent Development
11.16 MabPlex International
11.16.1 MabPlex International Company Detail
11.16.2 MabPlex International Business Overview
11.16.3 MabPlex International Antibody and Recombinant Protein CDMO Introduction
11.16.4 MabPlex International Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024)
11.16.5 MabPlex International Recent Development
11.17 Genscriptprobio
11.17.1 Genscriptprobio Company Detail
11.17.2 Genscriptprobio Business Overview
11.17.3 Genscriptprobio Antibody and Recombinant Protein CDMO Introduction
11.17.4 Genscriptprobio Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024)
11.17.5 Genscriptprobio Recent Development
11.18 Vetter
11.18.1 Vetter Company Detail
11.18.2 Vetter Business Overview
11.18.3 Vetter Antibody and Recombinant Protein CDMO Introduction
11.18.4 Vetter Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024)
11.18.5 Vetter Recent Development
11.19 Etinpro (Beijing) Co
11.19.1 Etinpro (Beijing) Co Company Detail
11.19.2 Etinpro (Beijing) Co Business Overview
11.19.3 Etinpro (Beijing) Co Antibody and Recombinant Protein CDMO Introduction
11.19.4 Etinpro (Beijing) Co Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024)
11.19.5 Etinpro (Beijing) Co Recent Development
11.20 Boehringer Ingelheim BioXcellence
11.20.1 Boehringer Ingelheim BioXcellence Company Detail
11.20.2 Boehringer Ingelheim BioXcellence Business Overview
11.20.3 Boehringer Ingelheim BioXcellence Antibody and Recombinant Protein CDMO Introduction
11.20.4 Boehringer Ingelheim BioXcellence Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024)
11.20.5 Boehringer Ingelheim BioXcellence Recent Development
11.21 Lonza
11.21.1 Lonza Company Detail
11.21.2 Lonza Business Overview
11.21.3 Lonza Antibody and Recombinant Protein CDMO Introduction
11.21.4 Lonza Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024)
11.21.5 Lonza Recent Development
11.22 3SBio Inc
11.22.1 3SBio Inc Company Detail
11.22.2 3SBio Inc Business Overview
11.22.3 3SBio Inc Antibody and Recombinant Protein CDMO Introduction
11.22.4 3SBio Inc Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024)
11.22.5 3SBio Inc Recent Development
11.23 Porton
11.23.1 Porton Company Detail
11.23.2 Porton Business Overview
11.23.3 Porton Antibody and Recombinant Protein CDMO Introduction
11.23.4 Porton Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024)
11.23.5 Porton Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Antibody and Recombinant Protein CDMO Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Antibody CDMO
Table 3. Key Players of Recombinant Protein CDMO
Table 4. Global Antibody and Recombinant Protein CDMO Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 5. Global Antibody and Recombinant Protein CDMO Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Antibody and Recombinant Protein CDMO Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Antibody and Recombinant Protein CDMO Market Share by Region (2019-2024)
Table 8. Global Antibody and Recombinant Protein CDMO Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Antibody and Recombinant Protein CDMO Market Share by Region (2025-2030)
Table 10. Antibody and Recombinant Protein CDMO Market Trends
Table 11. Antibody and Recombinant Protein CDMO Market Drivers
Table 12. Antibody and Recombinant Protein CDMO Market Challenges
Table 13. Antibody and Recombinant Protein CDMO Market Restraints
Table 14. Global Antibody and Recombinant Protein CDMO Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Antibody and Recombinant Protein CDMO Market Share by Players (2019-2024)
Table 16. Global Top Antibody and Recombinant Protein CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody and Recombinant Protein CDMO as of 2023)
Table 17. Ranking of Global Top Antibody and Recombinant Protein CDMO Companies by Revenue (US$ Million) in 2023
Table 18. Global 5 Largest Players Market Share by Antibody and Recombinant Protein CDMO Revenue (CR5 and HHI) & (2019-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Antibody and Recombinant Protein CDMO Product Solution and Service
Table 21. Date of Enter into Antibody and Recombinant Protein CDMO Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Antibody and Recombinant Protein CDMO Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Antibody and Recombinant Protein CDMO Revenue Market Share by Type (2019-2024)
Table 25. Global Antibody and Recombinant Protein CDMO Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Antibody and Recombinant Protein CDMO Revenue Market Share by Type (2025-2030)
Table 27. Global Antibody and Recombinant Protein CDMO Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global Antibody and Recombinant Protein CDMO Revenue Market Share by Application (2019-2024)
Table 29. Global Antibody and Recombinant Protein CDMO Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global Antibody and Recombinant Protein CDMO Revenue Market Share by Application (2025-2030)
Table 31. North America Antibody and Recombinant Protein CDMO Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 32. North America Antibody and Recombinant Protein CDMO Market Size by Country (2019-2024) & (US$ Million)
Table 33. North America Antibody and Recombinant Protein CDMO Market Size by Country (2025-2030) & (US$ Million)
Table 34. Europe Antibody and Recombinant Protein CDMO Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. Europe Antibody and Recombinant Protein CDMO Market Size by Country (2019-2024) & (US$ Million)
Table 36. Europe Antibody and Recombinant Protein CDMO Market Size by Country (2025-2030) & (US$ Million)
Table 37. Asia-Pacific Antibody and Recombinant Protein CDMO Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 38. Asia-Pacific Antibody and Recombinant Protein CDMO Market Size by Region (2019-2024) & (US$ Million)
Table 39. Asia-Pacific Antibody and Recombinant Protein CDMO Market Size by Region (2025-2030) & (US$ Million)
Table 40. Latin America Antibody and Recombinant Protein CDMO Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Latin America Antibody and Recombinant Protein CDMO Market Size by Country (2019-2024) & (US$ Million)
Table 42. Latin America Antibody and Recombinant Protein CDMO Market Size by Country (2025-2030) & (US$ Million)
Table 43. Middle East & Africa Antibody and Recombinant Protein CDMO Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Middle East & Africa Antibody and Recombinant Protein CDMO Market Size by Country (2019-2024) & (US$ Million)
Table 45. Middle East & Africa Antibody and Recombinant Protein CDMO Market Size by Country (2025-2030) & (US$ Million)
Table 46. Batavia Biosciences Company Detail
Table 47. Batavia Biosciences Business Overview
Table 48. Batavia Biosciences Antibody and Recombinant Protein CDMO Product
Table 49. Batavia Biosciences Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024) & (US$ Million)
Table 50. Batavia Biosciences Recent Development
Table 51. Grifols Company Detail
Table 52. Grifols Business Overview
Table 53. Grifols Antibody and Recombinant Protein CDMO Product
Table 54. Grifols Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024) & (US$ Million)
Table 55. Grifols Recent Development
Table 56. Cerbios-Pharma SA Company Detail
Table 57. Cerbios-Pharma SA Business Overview
Table 58. Cerbios-Pharma SA Antibody and Recombinant Protein CDMO Product
Table 59. Cerbios-Pharma SA Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024) & (US$ Million)
Table 60. Cerbios-Pharma SA Recent Development
Table 61. HALIX Company Detail
Table 62. HALIX Business Overview
Table 63. HALIX Antibody and Recombinant Protein CDMO Product
Table 64. HALIX Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024) & (US$ Million)
Table 65. HALIX Recent Development
Table 66. Biovian Oy Company Detail
Table 67. Biovian Oy Business Overview
Table 68. Biovian Oy Antibody and Recombinant Protein CDMO Product
Table 69. Biovian Oy Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024) & (US$ Million)
Table 70. Biovian Oy Recent Development
Table 71. Catalent Company Detail
Table 72. Catalent Business Overview
Table 73. Catalent Antibody and Recombinant Protein CDMO Product
Table 74. Catalent Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024) & (US$ Million)
Table 75. Catalent Recent Development
Table 76. Goodwin Biotechnology Company Detail
Table 77. Goodwin Biotechnology Business Overview
Table 78. Goodwin Biotechnology Antibody and Recombinant Protein CDMO Product
Table 79. Goodwin Biotechnology Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024) & (US$ Million)
Table 80. Goodwin Biotechnology Recent Development
Table 81. Merck Company Detail
Table 82. Merck Business Overview
Table 83. Merck Antibody and Recombinant Protein CDMO Product
Table 84. Merck Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024) & (US$ Million)
Table 85. Merck Recent Development
Table 86. Hangzhou Hs-biopharm Company Detail
Table 87. Hangzhou Hs-biopharm Business Overview
Table 88. Hangzhou Hs-biopharm Antibody and Recombinant Protein CDMO Product
Table 89. Hangzhou Hs-biopharm Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024) & (US$ Million)
Table 90. Hangzhou Hs-biopharm Recent Development
Table 91. Wuxibiologics Company Detail
Table 92. Wuxibiologics Business Overview
Table 93. Wuxibiologics Antibody and Recombinant Protein CDMO Product
Table 94. Wuxibiologics Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024) & (US$ Million)
Table 95. Wuxibiologics Recent Development
Table 96. Bioinnobio Company Detail
Table 97. Bioinnobio Business Overview
Table 98. Bioinnobio Antibody and Recombinant Protein CDMO Product
Table 99. Bioinnobio Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024) & (US$ Million)
Table 100. Bioinnobio Recent Development
Table 101. Thousand Oaks Biopharmaceuticals Company Detail
Table 102. Thousand Oaks Biopharmaceuticals Business Overview
Table 103. Thousand Oaks Biopharmaceuticals Antibody and Recombinant Protein CDMO Product
Table 104. Thousand Oaks Biopharmaceuticals Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024) & (US$ Million)
Table 105. Thousand Oaks Biopharmaceuticals Recent Development
Table 106. Eurogentec Company Detail
Table 107. Eurogentec Business Overview
Table 108. Eurogentec Antibody and Recombinant Protein CDMO Product
Table 109. Eurogentec Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024) & (US$ Million)
Table 110. Eurogentec Recent Development
Table 111. HJB Company Detail
Table 112. HJB Business Overview
Table 113. HJB Antibody and Recombinant Protein CDMO Product
Table 114. HJB Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024) & (US$ Million)
Table 115. HJB Recent Development
Table 116. Bibo Pharma Company Detail
Table 117. Bibo Pharma Business Overview
Table 118. Bibo Pharma Antibody and Recombinant Protein CDMO Product
Table 119. Bibo Pharma Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024) & (US$ Million)
Table 120. Bibo Pharma Recent Development
Table 121. MabPlex International Company Detail
Table 122. MabPlex International Business Overview
Table 123. MabPlex International Antibody and Recombinant Protein CDMO Product
Table 124. MabPlex International Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024) & (US$ Million)
Table 125. MabPlex International Recent Development
Table 126. Genscriptprobio Company Detail
Table 127. Genscriptprobio Business Overview
Table 128. Genscriptprobio Antibody and Recombinant Protein CDMO Product
Table 129. Genscriptprobio Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024) & (US$ Million)
Table 130. Genscriptprobio Recent Development
Table 131. Vetter Company Detail
Table 132. Vetter Business Overview
Table 133. Vetter Antibody and Recombinant Protein CDMO Product
Table 134. Vetter Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024) & (US$ Million)
Table 135. Vetter Recent Development
Table 136. Etinpro (Beijing) Co Company Detail
Table 137. Etinpro (Beijing) Co Business Overview
Table 138. Etinpro (Beijing) Co Antibody and Recombinant Protein CDMO Product
Table 139. Etinpro (Beijing) Co Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024) & (US$ Million)
Table 140. Etinpro (Beijing) Co Recent Development
Table 141. Boehringer Ingelheim BioXcellence Company Detail
Table 142. Boehringer Ingelheim BioXcellence Business Overview
Table 143. Boehringer Ingelheim BioXcellence Antibody and Recombinant Protein CDMO Product
Table 144. Boehringer Ingelheim BioXcellence Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024) & (US$ Million)
Table 145. Boehringer Ingelheim BioXcellence Recent Development
Table 146. Lonza Company Detail
Table 147. Lonza Business Overview
Table 148. Lonza Antibody and Recombinant Protein CDMO Product
Table 149. Lonza Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024) & (US$ Million)
Table 150. Lonza Recent Development
Table 151. 3SBio Inc Company Detail
Table 152. 3SBio Inc Business Overview
Table 153. 3SBio Inc Antibody and Recombinant Protein CDMO Product
Table 154. 3SBio Inc Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024) & (US$ Million)
Table 155. 3SBio Inc Recent Development
Table 156. Porton Company Detail
Table 157. Porton Business Overview
Table 158. Porton Antibody and Recombinant Protein CDMO Product
Table 159. Porton Revenue in Antibody and Recombinant Protein CDMO Business (2019-2024) & (US$ Million)
Table 160. Porton Recent Development
Table 161. Research Programs/Design for This Report
Table 162. Key Data Information from Secondary Sources
Table 163. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Antibody and Recombinant Protein CDMO Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Antibody and Recombinant Protein CDMO Market Share by Type: 2023 VS 2030
Figure 3. Antibody CDMO Features
Figure 4. Recombinant Protein CDMO Features
Figure 5. Global Antibody and Recombinant Protein CDMO Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 6. Global Antibody and Recombinant Protein CDMO Market Share by Application: 2023 VS 2030
Figure 7. Pharmaceutical Company Case Studies
Figure 8. Biotechnology Company Case Studies
Figure 9. Generic Company Case Studies
Figure 10. Antibody and Recombinant Protein CDMO Report Years Considered
Figure 11. Global Antibody and Recombinant Protein CDMO Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 12. Global Antibody and Recombinant Protein CDMO Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Antibody and Recombinant Protein CDMO Market Share by Region: 2023 VS 2030
Figure 14. Global Antibody and Recombinant Protein CDMO Market Share by Players in 2023
Figure 15. Global Top Antibody and Recombinant Protein CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody and Recombinant Protein CDMO as of 2023)
Figure 16. The Top 10 and 5 Players Market Share by Antibody and Recombinant Protein CDMO Revenue in 2023
Figure 17. North America Antibody and Recombinant Protein CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 18. North America Antibody and Recombinant Protein CDMO Market Share by Country (2019-2030)
Figure 19. United States Antibody and Recombinant Protein CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. Canada Antibody and Recombinant Protein CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Europe Antibody and Recombinant Protein CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Antibody and Recombinant Protein CDMO Market Share by Country (2019-2030)
Figure 23. Germany Antibody and Recombinant Protein CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. France Antibody and Recombinant Protein CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. U.K. Antibody and Recombinant Protein CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Italy Antibody and Recombinant Protein CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Russia Antibody and Recombinant Protein CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Nordic Countries Antibody and Recombinant Protein CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Asia-Pacific Antibody and Recombinant Protein CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Antibody and Recombinant Protein CDMO Market Share by Region (2019-2030)
Figure 31. China Antibody and Recombinant Protein CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Japan Antibody and Recombinant Protein CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. South Korea Antibody and Recombinant Protein CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Southeast Asia Antibody and Recombinant Protein CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. India Antibody and Recombinant Protein CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Australia Antibody and Recombinant Protein CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Latin America Antibody and Recombinant Protein CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Antibody and Recombinant Protein CDMO Market Share by Country (2019-2030)
Figure 39. Mexico Antibody and Recombinant Protein CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Brazil Antibody and Recombinant Protein CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Middle East & Africa Antibody and Recombinant Protein CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Antibody and Recombinant Protein CDMO Market Share by Country (2019-2030)
Figure 43. Turkey Antibody and Recombinant Protein CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Saudi Arabia Antibody and Recombinant Protein CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Batavia Biosciences Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2019-2024)
Figure 46. Grifols Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2019-2024)
Figure 47. Cerbios-Pharma SA Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2019-2024)
Figure 48. HALIX Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2019-2024)
Figure 49. Biovian Oy Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2019-2024)
Figure 50. Catalent Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2019-2024)
Figure 51. Goodwin Biotechnology Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2019-2024)
Figure 52. Merck Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2019-2024)
Figure 53. Hangzhou Hs-biopharm Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2019-2024)
Figure 54. Wuxibiologics Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2019-2024)
Figure 55. Bioinnobio Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2019-2024)
Figure 56. Thousand Oaks Biopharmaceuticals Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2019-2024)
Figure 57. Eurogentec Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2019-2024)
Figure 58. HJB Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2019-2024)
Figure 59. Bibo Pharma Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2019-2024)
Figure 60. MabPlex International Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2019-2024)
Figure 61. Genscriptprobio Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2019-2024)
Figure 62. Vetter Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2019-2024)
Figure 63. Etinpro (Beijing) Co Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2019-2024)
Figure 64. Boehringer Ingelheim BioXcellence Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2019-2024)
Figure 65. Lonza Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2019-2024)
Figure 66. 3SBio Inc Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2019-2024)
Figure 67. Porton Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2019-2024)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
